Beyond Bacteria: Is Bile Acid Ecology One of the Missing Pieces in Chronic SIBO?

Over the last several years, I have spent countless hours studying chronic gut dysfunction while working with individuals suffering from small intestinal bacterial overgrowth (SIBO), hydrogen sulfide overgrowth, mast cell activation syndrome (MCAS)-related gastrointestinal symptoms, post-infectious illness, impaired motility, fat malabsorption, and treatment-resistant digestive disorders.

One observation continues to emerge: many patients improve temporarily, yet very few achieve durable recovery.

That observation has pushed me away from asking, “Which microbe is causing the problem?” and toward a different question:

What changes inside the host continue selecting for that microbial ecosystem?

I do not believe chronic SIBO is simply a bacterial infection or an isolated problem of excessive microbial biomass. Bacteria are responding to biological conditions created by the host. Motility, post-infectious autoimmunity, epithelial metabolism, mitochondrial function, immune signaling, barrier integrity, bile-acid physiology, and microbial cross-feeding may all be interconnected parts of the same process.

One area that deserves far more investigation is bile acid ecology.

Most people learn that bile acids help digest fat. That is true, but it represents only one part of their physiological role. Bile acids also function as metabolic, immunological, endocrine, and microbial signaling molecules. They influence microbial selection, intestinal barrier integrity, mucosal immune tolerance, inflammatory signaling, motility, antimicrobial peptide production, gut hormone secretion, hepatic metabolism, and communication across the gut–liver axis.

Under normal physiology, the liver synthesizes the primary bile acids cholic acid and chenodeoxycholic acid from cholesterol. These bile acids are conjugated with glycine or taurine, stored in the gallbladder, and released into the small intestine following a meal. Most are reabsorbed in the terminal ileum through the apical sodium-dependent bile acid transporter, or ASBT, and returned to the liver through enterohepatic circulation. Only a relatively small proportion reaches the colon.

Once bile acids enter the colon, the microbiome begins transforming them. Many bacteria express bile salt hydrolase enzymes, which remove the attached glycine or taurine group. A much smaller group carries the multigene bai, or bile acid inducible, pathway, allowing free primary bile acids to be converted into hydrophobic secondary bile acids. Cholic acid becomes deoxycholic acid, while chenodeoxycholic acid becomes lithocholic acid.

This transformation is normal. Secondary bile acids are not inherently pathological and are part of healthy human physiology.

The more important question is what happens when the microbial ecosystem becomes so efficient at this conversion that the composition and signaling behavior of the bile-acid pool change dramatically.

Recently, while reviewing one particularly complex case of refractory gastrointestinal dysfunction, I encountered a stool bile-acid profile that immediately caught my attention. Cholic acid measured 0.09%. Chenodeoxycholic acid measured 0.60%. Total primary bile acids represented only 0.69% of the measured pool. Deoxycholic acid measured 50.76%, while lithocholic acid measured 41.42%. Total secondary bile acids represented 92.18%, producing an approximate secondary-to-primary ratio of 134:1.

Every individual measurement remained within the laboratory’s stated reference interval.

Viewed conventionally, nothing appeared dramatically abnormal.

Viewed as a biological system, however, the pattern suggested something very different:

Nearly every measurable primary bile acid reaching the colonic environment appeared to be undergoing microbial transformation into secondary bile acids.

This distinction matters. Laboratory reference intervals usually evaluate measurements individually. They do not always capture relationships between measurements, ecological proportions, metabolic flux, receptor exposure, or the functional meaning of the entire profile.

The patient’s metagenomic stool profile also demonstrated an elevated Clostridia Cluster XIVa index. This does not prove excessive bai-pathway activity. Taxonomic abundance alone cannot establish whether the dominant strains carry a functional bai operon, whether those genes are expressed, whether the required enzymes are active, where the transformation is occurring, or the actual rate of bile-acid conversion.

However, organisms associated with this broader ecological group, including Clostridium scindens and Clostridium hiranonis, may possess the enzymatic machinery required for 7α-dehydroxylation. The combination of extreme secondary bile-acid dominance and an elevated Cluster XIVa index therefore made increased microbial conversion biologically plausible, although it did not prove the mechanism.

The clinical behavior made the case even more interesting. Fat-rich meals consistently worsened symptoms, producing severe systemic reactions, visceral hypersensitivity, and loose stools. A bile-acid sequestrant produced meaningful improvement.

That response does not prove that deoxycholic acid or lithocholic acid directly caused the symptoms. Bile-acid sequestrants can alter luminal bile-acid exposure, intestinal secretion, transit, receptor signaling, microbial substrate availability, and the binding of other compounds. Nevertheless, the convergence of the biochemical pattern, microbial ecology, meal response, and treatment response raised an important question:

Could abnormal bile-acid transformation become one of the mechanisms that locks the host into chronic disease?

Hydrophobic secondary bile acids such as deoxycholic acid and lithocholic acid are not inherently harmful. At physiological concentrations, they participate in signaling through receptors including FXR, TGR5, the vitamin D receptor, and the pregnane X receptor.

FXR regulates bile-acid synthesis, antimicrobial peptide production, immune tolerance, barrier function, hepatic lipid metabolism, and enterohepatic feedback through fibroblast growth factor 19, or FGF19. When ileal FXR is activated, FGF19 enters the portal circulation and signals the liver to suppress CYP7A1, reducing new bile-acid synthesis.

TGR5 influences enteric motor function, glucagon-like peptide-1 secretion, macrophage activity, energy metabolism, and neuroendocrine communication. The vitamin D receptor and pregnane X receptor also contribute to barrier maintenance, antimicrobial defense, xenobiotic detoxification, and immune regulation.

The biological effect of a bile acid therefore cannot be reduced to “good” or “bad.” Its impact depends on concentration, conjugation state, anatomical location, exposure duration, transit time, microbial transformation, mucosal permeability, receptor distribution, hepatic clearance, and host metabolic capacity.

Experimental work has shown that excessive deoxycholic acid exposure can increase oxidative stress, disturb mitochondrial membrane function and calcium handling, activate inflammatory pathways such as NF-κB, and affect epithelial barrier biology. These effects may involve reactive oxygen species, inflammatory cytokines such as TNF-α and IL-6, and disruption of tight-junction proteins including ZO-1 and occludin.

However, a high stool percentage of DCA does not automatically prove tissue toxicity. Stool concentration is not identical to mucosal exposure, intracellular concentration, receptor activation, or systemic absorption. The effect depends on where the bile acids are located, how long they contact the tissue, whether they are conjugated or free, and how efficiently the host absorbs, transforms, and clears them.

The profile may also point toward altered FXR–FGF19 signaling. Chenodeoxycholic acid is a strong endogenous FXR activator. If primary bile acids are prematurely deconjugated, transformed, or inadequately delivered to the terminal ileum, normal FXR activation and FGF19 feedback could become disrupted. Reduced FGF19 signaling may fail to suppress hepatic CYP7A1 appropriately, contributing to uncoordinated bile-acid synthesis and flux.

A stool profile alone cannot establish this. More direct assessment could include FGF19, serum 7α-hydroxy-4-cholesten-3-one, total bile acids, transit evaluation, and detailed profiling of conjugated and unconjugated bile-acid species.

Another increasingly important area is microbial cross-feeding. The microbiome does not function as isolated species. One organism releases metabolites that become substrates for another. One deconjugates bile acids. Another transforms the resulting molecules. One produces lactate. Another uses lactate as an electron donor. Another metabolizes sulfur compounds. The final metabolic output is generated by the community rather than by one organism acting alone.

This becomes particularly relevant when considering taurine-conjugated bile acids and hydrogen sulfide.

I have encountered several patients who reported worsening after taking tauroursodeoxycholic acid, or TUDCA. That observation does not prove TUDCA is harmful, and it does not mean that everyone with SIBO or hydrogen sulfide symptoms should avoid it. TUDCA may have cytoprotective, choleretic, endoplasmic-reticulum-stabilizing, and mitochondrial benefits in appropriate contexts.

However, TUDCA is a taurine-conjugated bile acid. Certain bacterial strains possess bile salt hydrolase enzymes capable of cleaving taurine from conjugated bile acids. Once liberated, taurine enters the intestinal metabolic network and may provide a sulfur-containing substrate for specific organisms under the appropriate ecological conditions.

Organisms such as Bilophila wadsworthia are associated with taurine-derived sulfur metabolism, but it would be too simplistic to attribute all taurine metabolism to one species or pathway. The outcome depends on the organisms present, gene expression, competing substrates, available electron acceptors, intestinal pH, redox conditions, transit, and the host’s sulfide-detoxification capacity.

In one ecosystem, TUDCA may be beneficial or neutral. In another, extensive deconjugation and sulfur cross-feeding may increase substrate availability for hydrogen sulfide production.

This is why supplements cannot be evaluated only through their direct pharmacology.

A supplement does not enter an empty intestine. It enters a living ecosystem.

The same systems perspective applies to hydrogen sulfide. Hydrogen sulfide is not simply a toxin. At physiological concentrations, it functions as a signaling molecule involved in vascular regulation, neural signaling, redox biology, and mucosal defense. Healthy colonocytes possess dedicated sulfide-oxidation pathways involving sulfide oxidoreductase and downstream mitochondrial sulfur-handling enzymes.

Problems arise when sulfide production exceeds the host’s capacity to oxidize and clear it.

At sufficiently high local concentrations, hydrogen sulfide can bind to the heme-copper center of cytochrome c oxidase, or mitochondrial Complex IV, interfering with oxidative phosphorylation. The effect is concentration-dependent and may be reversible at lower exposures, but sustained excessive sulfide can impair ATP production, redox balance, and epithelial metabolism.

This is ecologically important because healthy colonocytes rely heavily on microbial-derived butyrate. They oxidize butyrate through mitochondrial β-oxidation and the tricarboxylic acid cycle, consuming substantial amounts of oxygen delivered by the mucosal circulation.

That oxygen consumption helps maintain physiological epithelial hypoxia near the luminal surface. This low-oxygen environment favors obligate anaerobes and limits organisms capable of respiratory metabolism.

If hydrogen sulfide inhibits mitochondrial respiration, inflammatory signaling suppresses butyrate transport or oxidation, or mitochondrial function becomes impaired through another mechanism, epithelial oxygen consumption may decline. Colonocytes may shift away from oxidative metabolism and toward greater glycolytic dependence.

When the epithelial oxygen sink weakens, more oxygen may diffuse toward the mucosal surface. Inflammation can also induce nitric oxide synthase and increase nitrate availability. Oxygen and nitrate provide high-energy terminal electron acceptors that facultative anaerobes can exploit.

Members of the Enterobacteriaceae family, including Escherichia coli and Klebsiella, are particularly capable of using respiratory electron acceptors to gain a competitive advantage over obligate anaerobic fermenters. This is not merely random bacterial growth. It is ecological selection driven by host-derived energy resources.

This may represent one of the missing links connecting mitochondrial dysfunction, microbial selection, inflammation, bile-acid disruption, and persistent relapse.

Importantly, I do not think this is simply a story about bile acids, hydrogen sulfide, butyrate, mitochondrial dysfunction, the migrating motor complex, or one bacterial species.

The more cases I review, the more interconnected these systems appear.

Motility influences bile-acid exposure and microbial clearance. Bile acids influence microbial selection, secretion, barrier function, and enteric signaling. Microbes deconjugate and transform bile acids. Released glycine, taurine, and secondary bile acids enter additional metabolic networks. Microbial metabolites influence mitochondria and immune signaling. Mitochondrial metabolism determines epithelial oxygen consumption. Oxygen gradients influence which microbes survive. Inflammation increases nitrate availability. Respiratory organisms use those electron acceptors and generate metabolites that further alter the host.

Each system feeds the next.

From this perspective, chronic SIBO begins to resemble a self-reinforcing ecological state rather than a simple overgrowth disorder.

An initial disruption such as food poisoning, antibiotic exposure, viral illness, inflammatory injury, altered bile flow, autonomic dysfunction, or another metabolic stressor may impair the migrating motor complex or regional gut physiology. Slower transit increases microbial persistence in the small intestine and may promote premature bile-acid deconjugation.

Premature deconjugation in the jejunum or proximal ileum can impair micelle formation, reduce fat absorption, and expose the small-intestinal mucosa to free bile acids. Fat malabsorption then changes the amount and composition of lipids reaching the colon, further modifying bile-acid metabolism and microbial substrate availability.

Impaired forward clearance may also permit retrograde movement from the colon toward the terminal ileum when ileocecal valve function or regional motility is compromised. However, retrograde migration should not be treated as the sole explanation for SIBO. Organisms already present at low abundance in the small intestine may expand locally when clearance, pH, oxygenation, bile exposure, pancreatic secretion, or immune control changes.

The relationship between microbial metabolites and motility is likely bidirectional. Impaired motility promotes microbial expansion, while sulfide, bile-acid signaling, inflammation, and other metabolites may further alter enteric neurons, smooth muscle, interstitial cells of Cajal, serotonin signaling, and motor coordination.

This creates the possibility of a chronic ecological trap: obligate anaerobic stability declines, secondary bile-acid proportions shift, sulfur substrates are redistributed, hydrogen sulfide rises beyond host clearance capacity, epithelial respiration falls, physiological hypoxia weakens, oxygen and nitrate become more available, facultative pathobionts expand, inflammation increases, and motility and bile-acid handling deteriorate further.

The altered environment then continues selecting for the same microbial functions that reinforce the dysfunction.

This may explain why so many patients improve transiently after antibiotics or antimicrobial therapy yet eventually relapse. Reducing microbial biomass may temporarily lower fermentation, gas production, sulfide generation, and immune stimulation. However, it does not necessarily restore motility, bile-acid homeostasis, epithelial bioenergetics, physiological hypoxia, barrier integrity, immune regulation, or sulfide oxidation.

If the host environment continues supplying the same selective pressures, the microbial community may return to a similar functional state, even if the exact species composition changes.

That distinction matters. The pathological feature may not always be one organism. It may be the persistence of a metabolic function such as sulfur respiration, nitrate respiration, excessive deconjugation, 7α-dehydroxylation, lactate accumulation, mucin degradation, or oxygen-tolerant growth.

Different organisms can occupy the same functional niche. Eliminating one may simply create space for another organism capable of performing the same metabolic role.

This is why chronic SIBO management may need to move beyond a narrow antimicrobial model. Microbial burden, anatomical location, virulence factors, resistance patterns, and metabolite production still matter, and antimicrobial treatment may be necessary in selected patients.

The larger question is whether treatment also restores the conditions that prevent the same ecological pattern from re-emerging.

One potential priority is restoration of the epithelial oxygen sink. PPAR-γ supports colonocyte fatty-acid oxidation and suppresses inducible nitric oxide synthase. Restoring oxidative metabolism could increase epithelial oxygen consumption, reduce oxygen and nitrate availability near the lumen, and weaken the respiratory advantage of facultative pathobionts.

However, simply adding butyrate may not be sufficient when transport, oxidation, mitochondrial function, or inflammatory signaling is impaired. Butyrate must enter the cell through transporters such as monocarboxylate transporter 1, be converted to butyryl-CoA, undergo β-oxidation, enter the tricarboxylic acid cycle, and support electron transport.

The relevant question is not merely whether butyrate is present, but whether the host can use it.

Bile-pool rebalancing may also be relevant. In cases with extreme secondary bile-acid dominance and clinical evidence of bile-acid intolerance, bile-acid sequestrants such as cholestyramine or colesevelam may temporarily reduce luminal exposure to hydrophobic bile acids. However, they can also reduce absorption of medications, fat-soluble vitamins, and other compounds. They are not a universal solution and do not prove that secondary bile acids should be eliminated.

Strategic substrate management may be necessary in individuals with active hydrogen sulfide overproduction, high deconjugation activity, and poor sulfide clearance. Temporarily limiting excessive sulfur or taurine flux may reduce substrate pressure, but long-term sulfur restriction could impair glutathione synthesis, protein structure, sulfation, methylation, and mitochondrial function. The goal should be controlled substrate flux while restoring the host’s capacity to process sulfide.

Motility, barrier integrity, and immune regulation must also be addressed. Migrating motor complex dysfunction may reflect post-infectious autoimmunity, autonomic dysfunction, connective-tissue disease, hypothyroidism, medication effects, enteric neuropathy, smooth-muscle dysfunction, structural abnormalities, or altered serotonin signaling.

Prokinetics may improve clearance, but they do not automatically correct bile-acid transformation, mitochondrial dysfunction, or mucosal inflammation. Likewise, bile-acid interventions may not restore motor function if the enteric nervous system remains impaired.

The central point is that no single intervention is likely to repair the entire network. Antimicrobials may reduce biomass. Prokinetics may improve clearance. Sequestrants may reduce bile-acid exposure. Dietary changes may modify substrate flow. Butyrate-related interventions may support epithelial metabolism. Mitochondrial support may improve oxidative capacity. Barrier-directed interventions may reduce immune activation.

The important question is whether these interventions are sequenced according to the dominant biological failure in the individual patient.

In one case, impaired motility may be primary. In another, bile-acid malabsorption may dominate. In another, mitochondrial sulfide clearance may be overwhelmed. In another, premature small-intestinal deconjugation may impair fat absorption. In another, inflammation may suppress normal epithelial metabolism.

The same diagnosis of “SIBO” may therefore describe several very different biological systems.

My current hypothesis is that many chronic SIBO cases persist because the host gradually loses the capacity to maintain the metabolic environment that normally selects for a stable microbiome. The microbes adapt to that altered environment, and their metabolites further reinforce the host dysfunction that selected them.

This model remains incomplete. A stool bile-acid profile cannot establish small-intestinal bile-acid physiology. Microbial taxonomy cannot prove metabolic flux. Improvement with a sequestrant cannot isolate one mechanism. Associations between secondary bile acids, hydrogen sulfide, mitochondrial function, and SIBO do not establish a universal causal pathway.

The hypothesis needs to be tested using longitudinal case data, metabolomics, metatranscriptomics, bile-acid speciation, transit assessment, inflammatory markers, mitochondrial function, sulfide clearance, FGF19 signaling, and treatment response.

Nevertheless, the pattern is difficult to ignore.

Motility influences bile-acid exposure. Bile acids influence microbial ecology. Microbes reshape bile acids. Microbial metabolites influence mitochondria. Mitochondria determine epithelial oxygen consumption. Oxygen gradients influence which microbes survive. Inflammation changes nitrate availability. Those organisms then generate metabolites that further alter the host.

For decades, chronic SIBO has often been approached like a gardener repeatedly spraying weeds. But if the soil itself has become chemically imbalanced and unable to support the original ecosystem, removing the weeds only creates temporary space for them—or functionally similar organisms—to return.

Bacteria are not acting maliciously. They are adapting to the biological conditions available to them.

When antimicrobial treatment repeatedly fails, it may not be because the bacteria are invincible. It may be because the host environment—defined by motility, epithelial oxygenation, mitochondrial bioenergetics, bile-acid signaling, immune regulation, barrier integrity, and substrate availability—continues selecting for the same dysfunctional microbial state.

If this hypothesis is correct, then one of the most important questions in chronic gut disease is no longer:

Which microbe should we eliminate?

Instead, it becomes:

What ecological conditions is the host continuously creating, and how do we restore the environment that naturally selects for a healthy microbial community?

That is the question I continue investigating with every case.